4881Оценка влияния загрязнения воздуха на здоровье: AirQ+ ввод многозональных данныхTechnical Documents · May 12, 2021
4882Évaluation de l'impact de la pollution atmosphérique sur la santé : les tables de survie avec AirQ+Technical Documents · May 12, 2021
4884Évaluation de l’impact de la pollution de l’air sur la santé : saisir des données sur plusieurs zones avec AirQ+Technical Documents · May 12, 2021
4885Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: interim guidance, 7 May 2021Technical Documents · May 11, 2021
4886Health and climate change: country profile 2021: Sao Tome and PrincipeTechnical Documents · May 11, 2021
4887Lista de dispositivos médicos prioritarios para la respuesta a la COVID-19 y especificaciones técnicas conexas: orientaciones provisionales, 19 de noviembre de 2020Technical Documents · May 11, 2021
4888Background document on the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: background document to the WHO Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm, 7 May 2021Technical Documents · May 11, 2021
4889Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: grading of evidence: evidence to recommendation tables, 7 May 2021Technical Documents · May 11, 2021
4891Access to health-care services for older persons and persons with disabilities living in Eastern Ukraine along the "line of contact"Technical Documents · May 10, 2021
4893WHO European Childhood Obesity Surveillance Initiative (COSI) Report on the fourth round of data collection, 2015–2017Technical Documents · May 7, 2021
4894Poliovirus containment: guidance to minimize risk for facilities collecting, handling or storing materials potentially infectious for polioviruses: web annex D, form 2: progress reporting form on preparations for poliovirus containment and completion of phase I of GAPIIITechnical Documents · May 7, 2021
4895Poliovirus containment: guidance to minimize risk for facilities collecting, handling or storing materials potentially infectious for polioviruses: web annex A: country and area specific poliovirus data, March 2021 updateTechnical Documents · May 7, 2021
4896Физическая активность: информационный бюллетень. Цели в области устойчивого развития: задачи в области здравоохраненияTechnical Documents · May 7, 2021
4897Poliovirus containment: guidance to minimize risk for facilities collecting, handling or storing materials potentially infectious for polioviruses: web annex C, form 1: facility reporting formTechnical Documents · May 7, 2021
4898Предварительные рекомендации по применению вакцины ChAdOx1-S [рекомбинантной] против COVID-19 (вакцина AstraZeneca COVID-19 AZD1222, SII Covishield, SK Bioscience): временное руководство (первый выпуск: 10 февраля 2021 г.; обновлено 21 апреля 2021 г.)Technical Documents · May 7, 2021
4899Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 ChAdOx1-S [recombinant] (vaccin anti-COVID-19 AZD1222 d’AstraZeneca, Covishield de SII, SK Bioscience) : orientations provisoires, publiées le 10 février 2021, actualisées le 21 avril 2021Technical Documents · May 7, 2021
4900Poliovirus containment: guidance to minimize risk for facilities collecting, handling or storing materials potentially infectious for polioviruses: web annex B: standard operating procedure for the identification, destruction or preparation for containment of poliovirus infectious or potentially infectious materialsTechnical Documents · May 7, 2021